UK Markets closed
  • FTSE 100

    7,542.95
    -20.90 (-0.28%)
     
  • FTSE 250

    22,743.35
    -215.13 (-0.94%)
     
  • AIM

    1,159.87
    -11.87 (-1.01%)
     
  • GBP/EUR

    1.1974
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.3680
    -0.0030 (-0.2216%)
     
  • BTC-GBP

    31,389.34
    -250.82 (-0.79%)
     
  • CMC Crypto 200

    1,037.76
    +12.02 (+1.17%)
     
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • DOW

    35,911.81
    -201.81 (-0.56%)
     
  • CRUDE OIL

    84.27
    +2.15 (+2.62%)
     
  • GOLD FUTURES

    1,817.30
    -4.10 (-0.23%)
     
  • NIKKEI 225

    28,124.28
    -364.85 (-1.28%)
     
  • HANG SENG

    24,383.32
    -46.45 (-0.19%)
     
  • DAX

    15,883.24
    -148.35 (-0.93%)
     
  • CAC 40

    7,143.00
    -58.14 (-0.81%)
     

Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Merck MRK announced that the European Commission approved its blockbuster anti-PD-1 drug, Keytruda, in combination with Eisai’s cancer drug Lenvima, for treating first-line kidney cancer and recurrent endometrial carcinoma.

The Keytruda combination is now approved for treating adults with advance renal cell carcinoma (RCC) or kidney cancer in the first-line setting. The combination regimen received approval for treating advanced endometrial carcinoma, which starts in the uterus, in adult patients whose disease has progressed on or after treatment with a platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation. Keytruda plus Lenvima were approved for both the indications in the United States in mid-2021.

The approval for first-line RCC was based on data from the phase III study — CLEAR/KEYNOTE-581 — that demonstrated that treatment with Keytruda plus Lenvima achieved statistically significant improvement in progression-free survival (“PFS”) compared to Pfizer’s PFE kidney cancer drug, Sutent (sunitinib). The combination regimen reduced the risk of disease progression or death by 61% compared to Pfizer’s Sutent.

Data from the CLEAR/KEYNOTE-581 study demonstrated that treatment with the Keytruda plus Lenvima extended the median PFS to 23.9 months from 9.2 months following treatment with Pfizer’s Sutent. Merck’s Keytruda in combination with Lenvima reduced the risk of death by 34% compared to PFE’s Sutent.

Please note that Keytruda, in combination with Pfizer’s Inlya (axitinib), is already indicated for the first-line treatment of adult patients with advanced RCC in Europe.

Meanwhile, the approval for the endometrial carcinoma indication was backed by data from another phase III study — KEYNOTE-775/Study 309. Data from the late-study demonstrated that Keytruda plus Lenvima improved overall survival and PFS by 38% and 44%, respectively. The improvements were statistically significant compared to chemotherapy.

Merck’s stock has declined 8.5% this year so far against an increase of 14.2% for the industry.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Label expansions of Keytruda in Europe to include first-line RCC and recurrent endometrial carcinoma represents a significant opportunity.

RCC is the most common type of kidney cancer that occurs in approximately 90% of patients diagnosed with kidney cancer. Last year, in Europe, more than 138,000 people were diagnosed with kidney cancer for the first time. The cancer was responsible for more than 54,000 deaths in the same year. It is estimated that there were more than 431,000 new cases of kidney cancer worldwide in 2020.

New cases of uterine body cancer were diagnosed in more than 130,000 patients in Europe last year. Endometrial carcinoma is the most common type of cancer in the uterus. There were more than 413,000 new cases of uterine body cancer worldwide in 2020.

Keytruda, approved for various oncology indications, is the key growth driver for Merck and further label expansion of the drug will aid the top line.

Merck & Co., Inc. Price

Merck & Co., Inc. Price
Merck & Co., Inc. Price

Merck & Co., Inc. price | Merck & Co., Inc. Quote

Zacks Rank & Stocks to Consider

Merck currently carries a Zacks Rank #3 (Hold).

A couple of better-ranked stocks from the pharma/biotech sector include GlaxoSmithKline GSK and Sarepta Therapeutics SRPT, both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Earnings per share estimates for Glaxo have moved north from $2.86 to $3.00 for 2021 and from $3.10 to $3.26 for 2022 in the past 30 days. Glaxo delivered an earnings surprise of 15.28%, on average, in the last four quarters. Shares of Glaxo have gained 12.4% so far this year.

Sarepta’s loss per share estimates have narrowed from $6.95 to $4.99 for 2021 and from $4.83 to $3.61 for 2022. Sarepta delivered an earnings surprise of 11.06%, on average, in the last four quarters.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline plc (GSK) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting